Equity Profile

TNGX

Tango Therapeutics, Inc.

Health CareBiotechnology$3.2B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercialize its therapies.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TNGX Q2-2026 Earnings Preview

Context

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies. Operating in the health care sector, Tango aims to harness genetic insights to create targeted treatments, which is increasingly important as personalized medicine gains traction.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+117.71%

Avg Stock Reaction

+2.19%

Last Quarter Recap

In Q1-2026, Tango reported an EPS of -$0.32, matching analyst expectations with a slight surprise. The stock reacted positively, gaining 8.55% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Tango Therapeutics are mixed, as there are no analyst estimates available. Investors are likely looking for signs of progress in its drug development pipeline.

Bull Case

The optimistic view hinges on strong advancements in clinical trials, potentially leading to positive revenue growth and improved EPS figures.

Bear Case

Conversely, if the company fails to show significant progress in its drug development or reports wider losses, it could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected timeline for upcoming clinical trial results?

The timeline for clinical trials can significantly impact investor sentiment and stock performance, as successful trials can lead to increased revenue potential.

How much has R&D spending increased compared to last quarter?

Increased R&D spending can indicate a commitment to innovation and future growth, which investors will closely watch.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Tango's drug pipeline to yield positive results sooner than expected, given recent advancements in biotechnology.

Supporting Evidence

The company's recent clinical trial results have shown promising early data that could lead to faster approvals.

Insider selling activity, while concerning, may not reflect the overall potential of the company's pipeline.

Key Risk

If the upcoming clinical trial results exceed expectations, it could significantly shift market perception and consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the risks of continued losses and the uncertainty of drug development timelines.

Bull Confirmed If

A clear indication of successful clinical trial results or a significant reduction in EPS losses would confirm the bull case.

Bear Confirmed If

Wider-than-expected losses or delays in clinical trial results would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±8.57%

Historical Avg

±14.0%

Pricing cheap

The options market is pricing in an 8.57% move, suggesting that traders expect some volatility around the earnings report.

Options are pricing ±8.6% while TNGX has averaged ±14.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

1.1%

30d HV

93.8%

Calls (1K)P/C Ratio: 1.21Puts (13K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$961,500.00

38,460 sh

1 insider

Net

$961,500.00

Net selling

Most Active Insiders· 1 open-market trade

President, R&DCrystal Adam
$961,500.00
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tango beats expectations, history suggests the stock could rise by around 0.09%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await clearer guidance.

Miss

A miss could lead to a decline, with history indicating an average drop of 5.68% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for clinical trial results.
2Details on R&D spending and its impact on future growth.
3Any new partnerships or collaborations that could enhance product development.
4Insights into market competition and how Tango plans to differentiate its therapies.
5Management's outlook on revenue growth for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Tango Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercialize its therapies.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TNGX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+117.71%

Avg Stock Reaction

+2.19%

Last Quarter Recap

In Q1-2026, Tango reported an EPS of -$0.32, matching analyst expectations with a slight surprise. The stock reacted positively, gaining 8.55% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Tango Therapeutics are mixed, as there are no analyst estimates available. Investors are likely looking for signs of progress in its drug development pipeline.

Bull Case

The optimistic view hinges on strong advancements in clinical trials, potentially leading to positive revenue growth and improved EPS figures.

Bear Case

Conversely, if the company fails to show significant progress in its drug development or reports wider losses, it could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected timeline for upcoming clinical trial results?

The timeline for clinical trials can significantly impact investor sentiment and stock performance, as successful trials can lead to increased revenue potential.

How much has R&D spending increased compared to last quarter?

Increased R&D spending can indicate a commitment to innovation and future growth, which investors will closely watch.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Tango's drug pipeline to yield positive results sooner than expected, given recent advancements in biotechnology.

Supporting Evidence

The company's recent clinical trial results have shown promising early data that could lead to faster approvals.

Insider selling activity, while concerning, may not reflect the overall potential of the company's pipeline.

Key Risk

If the upcoming clinical trial results exceed expectations, it could significantly shift market perception and consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for growth against the risks of continued losses and the uncertainty of drug development timelines.

Bull Confirmed If

A clear indication of successful clinical trial results or a significant reduction in EPS losses would confirm the bull case.

Bear Confirmed If

Wider-than-expected losses or delays in clinical trial results would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±8.57%

Historical Avg

±14.0%

Pricing cheap

The options market is pricing in an 8.57% move, suggesting that traders expect some volatility around the earnings report.

Options are pricing ±8.6% while TNGX has averaged ±14.0% over the last 8 prints — setup is pricing cheap.

Detail

ATM IV

1.1%

30d HV

93.8%

Calls (1K)P/C Ratio: 1.21Puts (13K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$961,500.00

38,460 sh

1 insider

Net

$961,500.00

Net selling

Most Active Insiders· 1 open-market trade

President, R&DCrystal Adam
$961,500.00
Net selling

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tango beats expectations, history suggests the stock could rise by around 0.09%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await clearer guidance.

Miss

A miss could lead to a decline, with history indicating an average drop of 5.68% following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the timeline for clinical trial results.
2Details on R&D spending and its impact on future growth.
3Any new partnerships or collaborations that could enhance product development.
4Insights into market competition and how Tango plans to differentiate its therapies.
5Management's outlook on revenue growth for the upcoming quarters.